Related Experiment Video
Updated: Aug 27, 2026

Modeling Chemotherapy Resistant Leukemia In Vitro
Published on: February 9, 2016
Chemoimmunotherapy with levamisole during maintenance therapy in children with acute lymphoblastic leukemia
Abstract:
Thirty seven children with acute lymphoblastic leukemia (All) treated according to 2 different protocols were randomized after remission induction to receive levamisole or not during remission maintenance continuous or intermittent polychemotherapy. The usefulness of levamisole in prolonged remission and survival time by the actuarial analysis were studied. At 36th month 45% patients treated with levamisole, and 30% without levamisole remained in complete remission. The increase of E+ lymphocyte and total lymphocyte count in the 18th week of chemoimmunotherapy, and their decrease in 27th week of the treatment were demonstrated. The granulocyte phagocytic activity increased in the 27th week of treatment. The results obtained suggest that levamisole therapy stimulates T lymphocyte production and phagocytic activity and enables the appropriate cytostatic treatment.
More Related Videos
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
08:31Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
Related Concept Videos
Treatment Resistant Cancers
Treatment Resistent Cancers
Tumor Immunotherapy
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Leishmaniasis